| Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. | |
| | |
MedLine Citation:
|
PMID: 20679615 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
|
Authors:
|
Eliza Hawkes; David Cunningham |
Related Documents
:
|
21061255 - Epcam- and egfr- targeted selective gene therapy for biliary cancers using z33-fiber mo... 21139045 - Nakiterpiosin targets tubulin and triggers mitotic catastrophe in human cancer cells. 17136225 - Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. 15736405 - Growth hormone receptor antagonist administration inhibits growth of human colorectal c... 15694815 - Hepatic arterial infusion after curative resection of colorectal cancer metastases: a m... 21532835 - Lung cancer: are we up to the challenge? |
Publication Detail:
|
Type: Comment; Letter Date: 2010-08-02 |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 28 ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: 2010-11-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: e529-31; author reply e532-e533 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Phosphatidylinositol 3-Kinase
/
genetics Antibodies, Monoclonal / therapeutic use* Antineoplastic Agents / therapeutic use Clinical Trials as Topic Colorectal Neoplasms / drug therapy*, genetics Drug Resistance, Neoplasm / genetics Gene Expression Regulation, Neoplastic Genes, ras / genetics Humans Mutation PTEN Phosphohydrolase / genetics Proto-Oncogene Proteins / genetics Proto-Oncogene Proteins B-raf / genetics Receptor, Epidermal Growth Factor / genetics Treatment Outcome Tumor Markers, Biological / genetics* ras Proteins / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/KRAS protein, human; 0/Proto-Oncogene Proteins; 0/Tumor Markers, Biological; EC 2.7.1.137/1-Phosphatidylinositol 3-Kinase; EC 2.7.1.137/PIK3CA protein, human; EC 2.7.1.37/BRAF protein, human; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.11.1/Proto-Oncogene Proteins B-raf; EC 3.1.3.48/PTEN protein, human; EC 3.1.3.67/PTEN Phosphohydrolase; EC 3.6.5.2/ras Proteins |
| Comments/Corrections | |
Comment On:
|
J Clin Oncol. 2009 Dec 10;27(35):5924-30
[PMID:
19884556
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
Next Document: Reply to S. Sciallero et al.